Importantly, as anti-TWEAK therapy has proven useful in preclinical models of autoimmune diseases, and as lower serum levels of TWEAK are associated with better outcomes, it is possible that TWEAK may also represent a viable therapeutic target in COVID-19 and similar infections. The gene discussed is TNFSF12; the disease is infection.